Bill of Health

MARCH 24, 2022

At the research and development (R&D) stage, government funders can bind producers to equity goals through targeted contractual provisions, as we explain in a recently-published Nature Biotechnology article. Consider, for instance, the case of COVID-19 vaccines. We summarize our proposals in the following sections.

COVID-19 Vaccine 130

COVID-19 Vaccine Licensing COVID-19 Public Health 130

Bill of Health

AUGUST 29, 2022

On October 8, 2020, Moderna, the maker of one of the first mRNA-based vaccines for COVID-19 and the recipient of billions of dollars of U.S. government funding, announced that it felt “a special obligation … to use our resources to bring this pandemic to an end as quickly as possible.” By Jorge L. Moderna’s Pledge.

COVID-19 Vaccine 362

COVID-19 Vaccine COVID-19 Licensing Governance 362

Bill of Health

SEPTEMBER 20, 2022

Monopoly control presents profound questions for public health governance. Consider the United States, for example, which made the unprecedented move to leave the World Health Organization (WHO) during the pandemic. The post Reclaiming Global Public Health appeared first on Bill of Health.

Public Health 246

Public Health COVID-19 World Health Governance 246

Health Law RX

NOVEMBER 5, 2021

An employee is considered “fully vaccinated” two weeks after completing primary vaccination with a COVID-19 vaccine with, if applicable, at least the minimum interval between doses as recommended by the CDC, World Health Organization (“WHO”), or if administered as a part of a clinical trial.

COVID-19 40

COVID-19 COVID-19 Vaccine ADA Medicaid 40